01
Cash & equivalents increased 62.8%
Cash & equivalents changed +62.8% from the comparable as-filed period.
$18.7M→$30.4MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTAligos Therapeutics, Inc.'s latest supported as-filed period reports revenue of $0, 100.0% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +62.8% from the comparable as-filed period.
Net income changed +90.5% from the comparable as-filed period.
Operating income changed +89.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ALGS · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-336851SEC ↗8-KAug 6, 2026Period Aug 6, 20260001171843-26-005294SEC ↗4Jun 29, 2026Period Jun 25, 20260001610717-26-000305SEC ↗4Jun 29, 2026Period Jun 25, 20260001610717-26-000304SEC ↗4Jun 29, 2026Period Jun 25, 20260001610717-26-000303SEC ↗4Jun 29, 2026Period Jun 25, 20260001610717-26-000302SEC ↗4Jun 29, 2026Period Jun 25, 20260001610717-26-000301SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 25, 2026Filed Jun 29, 2026 | Preston HeatherDirector | Grant Or AwardDirect | 5,860 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +72.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Revenue changed -100.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Stock-based compensation changed +17.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001610717-26-000300